Apigenin shows up in a lot of sleep and anxiety discussions online, usually attached to a single claim: it binds GABA-A receptors. That is true, but it is only one of several mechanisms researchers have documented for this flavone, and understanding the others explains why apigenin keeps appearing in cancer-prevention, skin, and metabolic research as well.
This article walks through what is actually known about how apigenin behaves once it is absorbed, without overstating what preclinical and early human data can support.
Disclosure: ApigeninHub is a participant in the Amazon Services LLC Associates Program. Some links in this article are affiliate links, and we may earn a commission on qualifying purchases at no extra cost to you.
What Apigenin Actually Is
Apigenin is a flavone, a subclass of flavonoid found in chamomile flowers, parsley, celery, and the skins of several fruits. Structurally, it is a relatively simple molecule compared to other flavonoids, which is part of why researchers have been able to study its receptor interactions in reasonable detail. Brain delivery is less settled: in rats apigenin reached the brain at about 1.2 micromolar after daily intraperitoneal injection of 20 mg/kg apigenin potassium salt for a week, and no brain levels from oral dosing in people are in the evidence [11][12].
Chamomile tea has been used traditionally for centuries as a mild calming beverage, and apigenin is often credited for that reputation, but researchers cannot tell whether the effects of chamomile extract come from apigenin, other components, or both [13][14].
GABA-A Receptor Modulation
The most studied mechanism is apigenin’s interaction with GABA-A receptors, the same receptor family targeted by benzodiazepines. Apigenin does bind the benzodiazepine site, competitively displacing flunitrazepam with a Ki near 4 micromolar, and it was anxiolytic in mice without sedation or muscle relaxation at benzodiazepine-comparable doses[1].
Research note: In rats made diabetic, apigenin injections raised serum testosterone above the untreated diabetic rats’ low level (p < 0.01); this restores a diabetes-lowered value and says nothing about healthy animals or people [23].
The direction of that modulation is where the popular account goes wrong. Apigenin is often described as a positive modulator that boosts GABA signalling. Patch-clamp recordings show the opposite: apigenin reversibly reduced GABA-evoked currents at alpha1beta2gamma2 receptors and decreased both the amplitude and the frequency of spontaneous inhibitory currents in cortical neurons, while also blocking NMDA-receptor responses with an IC50 around 10 micromolar[2]. Consistent with that, rats given apigenin showed reduced locomotor activity that flumazenil, the benzodiazepine antagonist, did not reverse, and apigenin failed to show anxiolytic activity in that study at all[3]. The honest summary is that apigenin binds the benzodiazepine site but does not behave like a benzodiazepine once bound, and the mechanism behind its calming reputation is still unresolved.
Cell studies also disagree on direction. In one oocyte study apigenin on its own inhibited GABA activation of human receptors and was not acting through the benzodiazepine site, yet at 1 microM it boosted diazepam’s enhancement of the GABA response by up to 22%. These are cell-culture concentrations, not supplement doses [19][20].
No study in the evidence tests dependence or withdrawal with apigenin, and no human trial shows that it sedates or improves sleep, so how people experience it is not established [15][16].
CD38 Inhibition and NAD+ Metabolism
A newer area of interest is apigenin’s activity as a CD38 inhibitor. CD38 is an enzyme that consumes NAD+, a coenzyme involved in cellular energy production and DNA repair that declines with age. Apigenin was characterised as a CD38 inhibitor that raised intracellular NAD+ levels and altered protein acetylation in a metabolic-syndrome model[4].
This mechanism is why apigenin sometimes appears in longevity and metabolic-health discussions alongside compounds like nicotinamide riboside. It is worth being precise here: the CD38 research is largely preclinical, and no human trial has established that oral apigenin supplementation meaningfully raises NAD+ levels in people.
The core numbers are test-tube and injected-animal results: apigenin inhibited purified human CD38 with an IC50 of 10.3 micromol/L, and the obese mouse result used daily injections of 100 mg/kg into the abdomen for a week. A review that reported mouse liver NAD+ nearly doubling was funded by Tally Health [4][13].
Antioxidant and Anti-Inflammatory Activity
Like most flavonoids, apigenin has demonstrated antioxidant properties in laboratory studies, scavenging free radicals and modestly upregulating the body’s own antioxidant enzyme systems through the Nrf2 pathway. It has also been shown in cell studies to reduce production of inflammatory signaling molecules such as TNF-alpha and IL-6.
These effects are consistent with the broader flavonoid class rather than unique to apigenin, but they help explain why researchers have studied it across such a wide range of conditions, from skin inflammation to joint health.
Effects on Aromatase and Hormone Pathways
Apigenin has been studied for its interaction with aromatase, the enzyme that converts androgens into estrogens. In a screen of 28 flavonoids against aromatase prepared from human placenta, apigenin was among the most potent inhibitors, with an IC50 near 0.9 micrograms per millilitre[5], which is part of why it has been researched in hormone-sensitive cancer models.
That result is an enzyme assay. In human adrenal cells apigenin’s aromatase inhibition coincided with some cytotoxicity at 100 microM, and in immature rats 50 mg/kg given by mouth did not cause uterine growth, which the authors linked to poor absorption or bioavailability [21][22].
This same property is why women researching natural estrogen modulation, and people curious about testosterone-related questions, often come across apigenin. The practical effect of oral supplementation on human hormone levels has not been established in controlled human trials, so claims in either direction should be treated as unproven.
CYP450 Enzyme Interactions
In laboratory studies apigenin inhibits several cytochrome P450 enzymes, including CYP1A2[6], CYP2C9, where it slowed metabolism of the blood-pressure drug losartan[7], and CYP3A4[8]. These enzymes metabolize a wide range of prescription medications, including warfarin, certain statins, and benzodiazepines. Because of this, anyone taking medications processed by these enzymes should talk to a doctor or pharmacist before adding apigenin.
Absorption and Bioavailability
Apigenin has relatively low oral bioavailability on its own, and there are human numbers for this. In healthy male adults, free apigenin was poorly absorbed [9], with metabolites equivalent to just 0.5 percent of intake recovered in urine, whereas the apigenin glycoside in a parsley drink reached 11.2 percent[9]. That is one reason formulation research is active, but those data come from rats and the lab: for example, nanocrystals gave a 3.6-fold higher peak plasma concentration than coarse powder in rats. Taking it with a meal containing some fat is a commonly recommended practice, though no human study in the evidence has tested it for apigenin [17][18].
Frequently Asked Questions
Is apigenin the same as CBD?
No. Apigenin is a plant flavone found in chamomile and other foods, while CBD is a cannabinoid derived from cannabis. They act on different receptor systems, though both have been studied for calming effects.
Does apigenin work the same way as melatonin?
No. Melatonin signals the body’s circadian clock, while apigenin’s proposed mechanism involves GABA-A receptor modulation. Some sleep formulations combine the two because they act on different pathways.
How long before apigenin’s mechanisms take effect?
Anecdotal reports describe a calming effect within 30 to 60 minutes, but rigorous human timing studies are limited. It is worth knowing that the one randomised, double-blind, placebo-controlled trial of standardised chamomile extract in chronic primary insomnia found no significant difference from placebo on its sleep diary measures[10].
Can apigenin’s mechanisms interact with my medication?
Possibly. Because apigenin inhibits several CYP450 enzymes, it can theoretically affect how the body metabolizes certain drugs. Speak with a healthcare provider if you take prescription medication.
These statements have not been evaluated by the FDA. Apigenin is not intended to diagnose, treat, cure, or prevent any disease. Talk to a qualified healthcare provider before starting any new supplement, especially if you take prescription medication.
References
- Viola H et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med (1995). PMID 7617761
- Losi G et al. Apigenin modulates GABAergic and glutamatergic transmission in cultured cortical neurons. Eur J Pharmacol (2004). PMID 15464088
- Zanoli P et al. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia (2000). PMID 10930722
- Escande C et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes (2013). PMID 23172919
- Jeong HJ et al. Inhibition of aromatase activity by flavonoids. Arch Pharm Res (1999). PMID 10403137
- Shimada H et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol (2010). PMID 20806393
- Wang Z et al. Inhibitory effect of apigenin on losartan metabolism and CYP2C9 activity in vitro. Pharmacology (2016). PMID 27287328
- Kondza M et al. Characterization of the CYP3A4 enzyme inhibition potential of selected flavonoids. Molecules (2021). PMID 34069400
- Borges G et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radic Biol Med (2022). PMID 35452808
- Zick SM et al. Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complement Altern Med (2011). PMID 21939549
- Venigalla M et al. Curcumin and Apigenin – novel and promising therapeutics against chronic neuroinflammation in Alzheimer's disease. Neural regeneration research (2015). PMID 26487830
- Shimazu R et al. Evaluation of Blood-Brain Barrier Permeability of Polyphenols, Anthocyanins, and Their Metabolites. Journal of agricultural and food chemistry (2021). PMID 34555897
- Kramer DJ et al. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in nutrition (2024). PMID 38476603
- Jay D. Amsterdam et al. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study. PubMed (2012). PMID 22894890
- Mastrofini GF et al. Modulating stress and sleep through a multi-compound dietary supplement: a randomized, double-blind, placebo-controlled trial. Journal of the International Society of Sports Nutrition (2026). PMID 42829807
- Atena Pasban et al. The Effect of Chamomile on Common Psychological Disorders Including Depression, Anxiety, Stress and Sleep Disorders: A Narrative Review. Iranian Journal of Psychiatry and Behavioral Sciences (2025). doi:10.5812/ijpbs-157547
- Zhang J et al. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2013). PMID 23305994
- Valentina Fiftianingrum et al. Advancements in Nanomedicine Platforms and Solid-State Engineering for Enhancing the Solubility of Apigenin: A Narrative Review. International Journal of Nanomedicine (2026). PMID 42910236
- Campbell EL et al. The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical pharmacology (2004). PMID 15451406
- Goutman JD et al. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. European journal of pharmacology (2003). PMID 12586201
- J. Thomas Sanderson Induction and Inhibition of Aromatase (CYP19) Activity by Natural and Synthetic Flavonoid Compounds in H295R Human Adrenocortical Carcinoma Cells. Toxicological Sciences (2004). PMID 15319488
- Saarinen N et al. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. The Journal of steroid biochemistry and molecular biology (2001). PMID 11595503
- Khaled M et al. Apigenin ameliorates genitourinary dysfunction in a type 1 diabetic rat model via Drp1 modulation. Scientific reports (2024). PMID 38459102
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
